87 related articles for article (PubMed ID: 9360373)
1. [Structure and function of influenza virus neuraminidase].
Itamura S
Nihon Rinsho; 1997 Oct; 55(10):2570-4. PubMed ID: 9360373
[TBL] [Abstract][Full Text] [Related]
2. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor.
Varghese JN; McKimm-Breschkin JL; Caldwell JB; Kortt AA; Colman PM
Proteins; 1992 Nov; 14(3):327-32. PubMed ID: 1438172
[TBL] [Abstract][Full Text] [Related]
3. Influenza virus neuraminidase: structure, antibodies, and inhibitors.
Colman PM
Protein Sci; 1994 Oct; 3(10):1687-96. PubMed ID: 7849585
[TBL] [Abstract][Full Text] [Related]
4. [The receptor destroying enzyme of influenza viruses. The role of the receptor destroying enzyme on the budding and the release of influenza viruses from the host cells].
Suzuki Y
Nihon Rinsho; 1997 Oct; 55(10):2660-5. PubMed ID: 9360387
[TBL] [Abstract][Full Text] [Related]
5. [Function of neuraminidase of influenza virus and anti influenza compounds by its inhibition].
Yamashita M
Tanpakushitsu Kakusan Koso; 2009 Aug; 54(10):1284-91. PubMed ID: 19663256
[No Abstract] [Full Text] [Related]
6. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase.
Varghese JN; Epa VC; Colman PM
Protein Sci; 1995 Jun; 4(6):1081-7. PubMed ID: 7549872
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Chand P; Babu YS; Bantia S; Chu N; Cole LB; Kotian PL; Laver WG; Montgomery JA; Pathak VP; Petty SL; Shrout DP; Walsh DA; Walsh GM
J Med Chem; 1997 Dec; 40(25):4030-52. PubMed ID: 9406595
[TBL] [Abstract][Full Text] [Related]
8. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs.
von Itzstein M; Dyason JC; Oliver SW; White HF; Wu WY; Kok GB; Pegg MS
J Med Chem; 1996 Jan; 39(2):388-91. PubMed ID: 8558506
[TBL] [Abstract][Full Text] [Related]
9. A secondary sialic acid binding site on influenza virus neuraminidase: fact or fiction?
Lai JC; Garcia JM; Dyason JC; Böhm R; Madge PD; Rose FJ; Nicholls JM; Peiris JS; Haselhorst T; von Itzstein M
Angew Chem Int Ed Engl; 2012 Feb; 51(9):2221-4. PubMed ID: 22281708
[No Abstract] [Full Text] [Related]
10. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid.
Bossart-Whitaker P; Carson M; Babu YS; Smith CD; Laver WG; Air GM
J Mol Biol; 1993 Aug; 232(4):1069-83. PubMed ID: 8371267
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking and QSAR studies on substituted acyl(thio)urea and thiadiazolo [2,3-alpha] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase.
Sun J; Cai S; Mei H; Li J; Yan N; Wang Q; Lin Z; Huo D
Chem Biol Drug Des; 2010 Sep; 76(3):245-54. PubMed ID: 20626407
[TBL] [Abstract][Full Text] [Related]
12. In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.
Liu H; Yao X; Wang C; Han J
Mol Pharm; 2010 Jun; 7(3):894-904. PubMed ID: 20420444
[TBL] [Abstract][Full Text] [Related]
13. Design of a mechanism-based probe for neuraminidase to capture influenza viruses.
Lu CP; Ren CT; Lai YN; Wu SH; Wang WM; Chen JY; Lo LC
Angew Chem Int Ed Engl; 2005 Oct; 44(42):6888-92. PubMed ID: 16215975
[No Abstract] [Full Text] [Related]
14. Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Nair PC; Sobhia ME
Eur J Med Chem; 2008 Feb; 43(2):293-9. PubMed ID: 17513019
[TBL] [Abstract][Full Text] [Related]
15. Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding.
Smith BJ; Huyton T; Joosten RP; McKimm-Breschkin JL; Zhang JG; Luo CS; Lou MZ; Labrou NE; Garrett TP
Acta Crystallogr D Biol Crystallogr; 2006 Sep; 62(Pt 9):947-52. PubMed ID: 16929094
[TBL] [Abstract][Full Text] [Related]
16. Complexity in influenza virus targeted drug design: interaction with human sialidases.
Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
[TBL] [Abstract][Full Text] [Related]
17. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
[TBL] [Abstract][Full Text] [Related]
18. Anti-influenza drugs: the development of sialidase inhibitors.
von Itzstein M; Thomson R
Handb Exp Pharmacol; 2009; (189):111-54. PubMed ID: 19048199
[TBL] [Abstract][Full Text] [Related]
19. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
20. Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates.
Katinger D; Mochalova L; Chinarev A; Bovin N; Romanova J
Arch Virol; 2004 Nov; 149(11):2131-40. PubMed ID: 15503202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
